We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes (REPAMET)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00709917
First Posted: July 3, 2008
Last Update Posted: March 3, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
June 30, 2008
July 3, 2008
March 3, 2016
March 2007
January 2008   (Final data collection date for primary outcome measure)
  • Safety (number of hypoglycaemic incidents) [ Time Frame: After 10-20 weeks ]
  • HbA1C [ Time Frame: After 10-20 weeks ]
Same as current
Complete list of historical versions of study NCT00709917 on ClinicalTrials.gov Archive Site
  • safety [ Time Frame: After 10-20 weeks ]
  • posology [ Time Frame: After 10-20 weeks ]
  • lifestyle [ Time Frame: After 10-20 weeks ]
  • FBG [ Time Frame: After 10-20 weeks ]
Same as current
Not Provided
Not Provided
 
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes
Observational Study Investigating the Efficacy of Switching From Metformin Monotherapy to a Dual Therapy of Metformin and Repaglinide on Glycaemic Control in Type 2 Diabetes

This study is conducted in Europe.

The aim of this observational study is to investigate the switch from metformin alone to metformin combined with repaglinide in type 2 diabetic patients not achieving adequate glycaemic control on maximal dose of metformin given alone and to analyse different epidemiological parameters.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Type 2 diabetic patients having failed on metformin monotherapy
  • Diabetes
  • Diabetes Mellitus, Type 2
Drug: repaglinide
Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
Other Names:
  • AGEE
  • Prandin®
A
Intervention: Drug: repaglinide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2171
January 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetic patients with inadequate glycaemic control when received metformin alone on maximal dose
  • Signed informed consent
  • Treatment in accordance with the summary of product characterisation

Exclusion Criteria:

  • Any contraindication to metformin or repaglinide
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Luxembourg
 
 
NCT00709917
AGEE-1857
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
March 2016